EMEA-002270-PIP04-20 - paediatric investigation plan

Marzeptacog alfa (activated)
PIPHuman

Key facts

Active Substance
Marzeptacog alfa (activated)
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0482/2021
PIP number
EMEA-002270-PIP04-20
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Treatment of Haemophilia B
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Catalyst Biosciences, Inc.

Email: cdemocko@catbio.com    
Tel. +1 4153054942

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page